US FDA accepts for review an application for approval of nasal dihydroergotamine mesylate (INP1041) for the acute treatment of migraine

INP1041 is dihydroergotamine mesylate delivered directly into the vascular-rich upper nasal space, using a novel delivery system (Precision Olfactory Delivery [POD®]). The application is supported by safety results from the Phase III STOP 301 study.

Source:

Biospace Inc.